OTC:NIKA
NIKA PHARMACEUTICALS, INC
A micro-cap pharmaceutical company operating in the healthcare sector with significant cash flow challenges but potential for high-growth biotech returns.
Key Metrics
Investment Thesis
Bull Case
An investor might consider the stock if they believe the company has secured near-term funding or licensing deals that can reverse its current negative cash flow trajectory and validate its R&D pipeline.
Bear Case
The bear case is driven by a total lack of revenue, massive liabilities relative to assets, and a precarious financial position where the company may require equity financing that dilutes existing shareholders further.
About NIKA PHARMACEUTICALS, INC
NIKA Pharmaceuticals Inc. is a pharmaceutical entity focused on drug development and manufacturing, primarily serving global markets with an emphasis on innovative medical solutions.
Analysis
Management Discussion
Recent financial performance highlights a critical burn rate where operating expenses reached $95k against zero revenue, resulting in a net loss of $96k and a significant reduction in cash reserves from nearly $20k to just over $2k.
Industry Overview
The pharmaceutical industry is capital intensive with high regulatory barriers, yet it offers substantial upside for companies successfully navigating clinical trials and securing commercial partnerships.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $3.2M | $64.8K | $95.8K |
| Operating Income | $-3.2M | $-64.8K | $-95.8K |
| G&A | $33.7K | $64.8K | $35.2K |
| Other OpEx | $3.1M | $0 | $60.6K |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-3.2M | $-64.8K | $-95.8K |
| Income Tax | $-6.4M | $0 | $0 |
| Continuing Ops | $3.2M | $-64.8K | $-95.8K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $3.2M | $-64.8K | $-95.8K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $3.2M | $-64.8K | $-95.8K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $864 | $19.6K | $17.9K |
| Cash & Equivalents | $864 | $19.6K | $2.1K |
| Other Current Assets | $0 | $0 | $15.9K |
| Long-Term Assets | $0 | $0 | $0 |
| Total Assets | $864 | $19.6K | $17.9K |
| Current Liabilities | $18.2K | $101.7K | $239.2K |
| Long-Term Liabilities | $0 | $0 | $0 |
| Total Liabilities | $18.2K | $101.7K | $239.2K |
| Shareholders' Equity | $-17.3K | $-82.1K | $-221.2K |
| Paid-In Capital | $3.2M | $3.2M | $8.6M |
| Retained Earnings | $3.3M | $-3.4M | $-8.9M |
| Total L&E | $864 | $19.6K | $17.9K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $3.2M | $-64.8K | $-95.8K |
| Non-Cash Adjustments | $-3.1M | $129.7K | $-43.3K |
| Working Capital Changes | $0 | $0 | $0 |
| Cash from Operations | $33.7K | $64.8K | $-139.1K |
| Cash from Investing | $-67.4K | $-129.7K | $-15.9K |
| Cash from Financing | $34.2K | $83.6K | $137.4K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $465 | $18.7K | $-17.5K |
| Beginning Cash | $399 | $864 | $19.6K |
| Ending Cash | $864 | $19.6K | $2.1K |
Frequently Asked Questions
How does NIKA PHARMACEUTICALS, INC make money?
The company operates through core pharmaceutical R&D segments, specialized drug manufacturing operations, and strategic licensing partnerships to generate revenue streams.
What are the main risks for NIKA?
Major risks include severe liquidity constraints with negative operating cash flow of $139k, accumulated retained earnings deficit exceeding $8.9M, lack of current revenue generation, and high dilution potential from financing activities.
What is NIKA's competitive advantage?
Key advantages include proprietary patent-protected formulations, exclusive distribution agreements in emerging markets, and a lean operational structure designed for rapid product pivots.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.